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Abstract
Background and objective: Located on chromosome locus 5p15.33, telomerase
reverse transcriptase (TERT or hTERT) encodes the catalytic subunit of telomerase
which permits lengthening and preservation of telomeres following mitosis. Muta-
tions in TERT promoter (TERT-p) upregulate expression of TERT, allowing survival of
malignant cells and tumor progression in wide variety of malignancies including mela-
noma. The objective of this review is to examine the roles of TERT and TERT-p in the
pathogenesis, diagnosis, and prognostication of cutaneous melanoma.
Methods: All studies of TERT or TERT-p in cutaneous melanocytic neoplasms with
the following inclusion criteria were reviewed: publication date between 2010 and
2019, English language, and series of ≥3 cases were reviewed for evidence
supporting the role of TERT in pathogenesis, diagnosis, and prognosis. Studies with
<3 cases or focused primarily on mucosal or uveal melanocytic tumors were
excluded.
Results and conclusion: TERT-p mutations are frequent in chronic and non-chronic
sun damage melanoma and correlate with adverse prognosis, inform pathogenesis,
Abbreviations: AJCC, American Joint Committee on Cancer; ALM, acral lentiginous melanoma; AM, acral melanoma; AN, acral nevus; CSD, chronic sun damage; DM, desmoplastic melanoma;
DNA, deoxyribonucleic acid; ETS, E26 transformation specific; FISH, fluorescence in situ hybridization; GCN, giant congenital nevus; IHC, immunohistochemistry; ISH, in situ hybridization; LM,
lentigo maligna; LMM, LM melanoma; MAPK, mitogen-activated protein kinase; MDM, mixed desmoplastic melanoma; MIS, melanoma in situ; MM, metastatic melanoma; MPM, multiple primary
melanoma; MUP, melanoma of unknown primary; NGS, next-generation sequencing; NM, nevoid melanoma; PCR, polymerase chain reaction; PDM, pure desmoplastic melanoma; PHH3,
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and may provide diagnostic support. While TERT-p mutations are uncommon in acral
melanoma, TERT copy number gains and gene amplification predict reduced survival.
Among atypical spitzoid neoplasms, TERT-p mutations identify biologically aggressive
tumors and support the diagnosis of spitzoid melanoma. TERT-p methylation may
have prognostic value in pediatric conventional melanoma and drive tumorigenesis in
melanoma arising within congenital nevi. Finally, TERT-p mutations may aid in the dif-
ferentiation of recurrent nevi from recurrent melanoma.
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1 | INTRODUCTION
In the pedigree of a melanoma-prone family, a unique germline T > G
mutation was identified within the telomerase reverse transcriptase
promoter (TERT-p), located 57 bp upstream from the ATG translation
start site of TERT (5p15.33). This mutation creates a binding motif for
E26 transformation-specific (ETS) transcription factors and ternary
complex factors (TCFs) that increase TERT expression.1,2 ETS tran-
scription factors are expressed in early nevogenesis, prior to
extranucleolar telomerase localization and activity.3 Horn et al initially
sequenced TERT-p in sporadic primary and metastatic melanomas.
While these tumors did not harbor the familial mutation, recurrent
and mutually exclusive ultraviolet (UV)-signature (C > T or CC > TT)
mutations within a 49 bp region −100 bp upstream from the ATG
start site were identified. Similar to the germline mutation, these UV-
signature mutations created ETS/TCF binding motifs. The two most
common mutations (“hotspot”) were located at −124 bp (C > T) and
−146 bp (C > T). Two tandem mutations (CC > TT) at −124/−125 and
−138/−139 were also identified, and the latter may result from a sin-
gle mutation at −138 because the base mutation at −139 may occur
as a polymorphism (rs35550267).1,2
Expression of TERT by RT-PCR demonstrated overlapping pro-
files in dysplastic nevi and melanoma, suggesting the role of TERT in
precursor lesions.4 Targeted sequencing of 293 cancer genes was per-
formed in 37 primary melanomas with adjacent precursor lesions by
Shain et al. In precursor lesions, including intermediate melanocytic
neoplasms and melanomas in situ (MIS), 77% harbored TERT-p muta-
tions. In contrast, all unequivocally benign areas harbored BRAF
V600E mutations only. In contrast, biallelic inactivation of CDKN2A
and copy-number alterations were later events only observed in inva-
sive melanoma, while PTEN and TP53 mutations were limited to
advanced tumors. Thus, TERT-p mutations are selected at an early age
of tumorigenesis and represent the earliest secondary alterations in
intermediate neoplasms and MIS. Benign precursors with alterations
within the mitogen-activated protein kinase (MAPK) pathway may
persist through TERT-p mutations and then acquire subsequent muta-
tions resulting in progression toward melanoma.5
Accordingly, TERT-p mutations in otherwise benign nevi should
be interpreted with caution and are not synonymous with malignancy.
TERT-p hotspot mutations have been identified in an acquired dermal
and an acquired compound nevus, both in adults >50 years of age. In
this context, TERT-p mutant subclones may be indicative of early UV-
induced transformation.6 Two examples of dysplastic nevi with mod-
erate atypia based on consensus diagnosis by expert
dermatopathologists also harbored TERT-p hotspot mutations.7
Focused primarily on molecular analysis, this review examines the
roles of TERT and TERT-p in pathogenesis and their potential diagnos-
tic and prognostic utility in cutaneous melanoma. The majority of the
citied studies evaluated TERT-p mutational status by PCR amplifica-
tion followed by direct Sanger sequencing.
2 | NONACRAL MELANOMA INCLUDING
CHRONIC SUN DAMAGE AND NON-
CHRONIC SUN DAMAGE MELANOMA
2.1 | Pathogenesis
In multiple series primarily composed of primary chronic sun damage
(CSD) and non-CSD melanomas, TERT-p mutations (predominantly UV
signature, including hotspot and tandem mutations) have been
detected in 22% to 78% of tumors,8-17 and Heidenreich et al found
that their detection correlates with increased TERT mRNA expres-
sion.8 TERT-p UV-signature mutations correlate with chronic8,17 sun
exposure, and both the −124:C > T and the −146 C > T hotspot
mutations are associated with the CSD melanoma subtype (lentigo
maligna, LM).15 UV-signature mutations also result from intermit-
tent8,9 sun exposure and are associated with non-CSD melanomas,
including superficial spreading melanoma (SSM)9 and nodular mela-
noma (NM) subtypes.8-10,15,16 Accordingly, TERT-p hotspot mutations
are also significantly associated with Caucasian race, location on the
upper extremities or head/neck, and nonacral tumors.16,17 Less com-
mon non-UV-signature mutations, such as somatic −57 A > C muta-
tions previously described as familial melanoma mutations, have also
been detected in CSD and non-CSD melanomas by Heidenreich
et al.8 Concurrent BRAF mutations are significantly associated with
TERT-p mutations in CSD and non-CSD melanomas,10,11,14,15 particu-
larly BRAF 600 including BRAF V600E mutations.8,9 TERT-p UV-
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TABLE 1 Nonacral melanoma including CSD and non-CSD melanoma8-18
Author and year Number of cases Demographic Follow-up Major findings
Heidenreich et al8 264 Adults TERT-p mutations in 38% of melanomas associated
with Breslow thickness >2 mm, vertical growth
phase, ulceration, LNM and distant metastasis,
BRAF 600 or NRAS mutations, and TERT mRNA
expression
Populo et al9 116 Adults with mean age 60 y 54-57 mo
(mean)
TERT-p UV-signature mutations in 22% associated
with increased Breslow thickness, ulceration,
mitotic index, BRAF V600E mutation, and
decreased disease-free and overall survival; IHC
(nuclear and cytoplasmic expression) did not
correlate with prognostic features or survival
Macerola et al10 53 Adults with mean age 58 y
(range 20-87)
TERT-p mutations in 38% of tumors; concomitant
TERT-p and BRAF mutations in 21% associated
with Breslow depth, mitotic index, ulceration,
absence of regression, and LNM
Nagore et al11 300 47 mo
(median)
TERT-p mutations in 38.7% of tumors; concomitant
TERT-p and BRAF or NRAS mutations associated
with shorter melanoma-specific survival;
mutations did not negatively impact prognosis in
carriers of rs2853669 polymorphism
Nagore et al12 285 TERT-p mutations with or without concomitant BRAF
or NRAS mutations in 43% of tumors associated
with fast-growinga tumors; mutations had less




100 TERT-p mutations in 30% associated with absence of
regression, increased Breslow depth, ulceration,
and mitotic index
Roh et al13 30 TERT-p hotspot mutations in 27% but not
prognostic; concomitant TERT-p and BRAF V600E
mutations associated with decreased overall
survival
Bai et al14 615 29 mo
(median)
TERT-p mutations in CSD and non-CSD melanomas




287 TERT-p hotspot or tandem mutations in 41%
associated with Breslow depth >2 cm, mitotic
index, concomitant BRAF or NRAS mutations, and
disease recurrence; TERT-p −124:C > T hotspot
and −138/−139 CC > TT tandem mutations
associated with tumor stage > IB and disease-
specific death; tandem mutation associated with
worse disease-free and melanoma-specific survival






TERT-p mutations in 70.4% associated with visceral
metastasis as the first site of disease progression
in non-CSD melanoma of the trunk





TERT-p hotspot mutations were 98.6% specific and
77.9% sensitive for the diagnosis of melanoma;
hotspot mutations were not associated with
prognostic pathologic features
Abbreviations: CSD, chronic sun damage; IHC, immunohistochemistry; LNM, lymph node metastasis; non-CSD, non-chronic sun damage; TERT-p, TERT
promoter; UV, ultraviolet.
a≥0.5 mm Breslow thickness/mo.
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signature mutations are also associated with concurrent NRAS muta-
tions.8,11,15 While BRAF and NRAS mutations are early events, TERT-p
mutation and subsequently increased telomerase expression may
facilitate stabilization of a transformed genome (Table 1).8
2.2 | Diagnosis
Thomas et al identified TERT-p hotspot and UV-signature tandem
mutations in 78% of primary melanomas, 1.4% of melanocytic nevi,
and 5% of diagnostically equivocal melanocytic proliferations. Over
80% of tumors in this series were CSD or non-CSD melanomas.17
TERT-p hotspot and tandem mutations were 98.6% specific and
77.9% sensitive for the diagnosis of melanoma, with an overall accu-
racy of 87.3%. Of note, these figures do not account for TERT-p muta-
tions that do not form ETS/TCF sites: 9.7% of nevi and 2.3% of
melanomas harbored “non-ETS” mutations. TERT-p hotspot muta-
tional status did not differ significantly between CSD (LM) and non-
CSD (SSM, NM).17 By contrast, in a Korean series of 12 CSD melano-
mas and 18 non-CSD melanomas, Roh et al observed TERT-p hotspot
mutations in only 33.3% and 22.2% of tumors, and none of these
tumors harbored the CC > TT tandem mutation. Differences in race,
geography, and sample size may have contributed to these contrasting
results.13
2.3 | Prognosis
Including hotspot mutations, TERT-p mutations have been associated
with increased patient age at diagnosis,15 particularly ≥65 years.8,17
Increased Breslow thickness,9,10,16 specifically >2 mm,8,15 is also asso-
ciated with hotspot mutations. Vertical growth phase and advanced
tissue pathologic staging (tumor stage >IB) correlate with TERT-p
mutational status.8,10,15 Compared to WT tumors, ulceration,8,9,15,16
and higher mitotic rates9,10,15,16 (≥1 mm2) are also more frequent in
TERT-p mutants. Compared to TERT-p and BRAF wild-type tumors,
concurrent mutations affect more prognostic variables than either
mutation alone, including increased Breslow thickness, higher mean
mitotic rate, and ulceration.10 TERT-p mutations are significantly asso-
ciated with the absence of regression,10,16 particularly in the context
of concomitant TERT-p and BRAF mutations.10 Unamuno Bustos et al
studied TERT-p mutations in 110 melanomas, the largest group show-
ing no regression (47%), 41% with partial regression, and 12% with
>50% or extensive regression. In contrast, all tumors with extensive
regression were WT for TERT-p, suggesting that an absence of telo-
merase expression may permit telomere shortening and subsequent
regression.16 However, in a recent study of diagnostic utility with pre-
dominantly nonacral primary melanomas, there was no association
between TERT-p hotspot mutations and Breslow thickness, ulceration,
mitotic index, American Joint Committee on Cancer tumor stage,
regression, or tumor infiltrating lymphocytes.17
Lymph node metastasis8,10 and distant metastasis8,18 were asso-
ciated with TERT-p mutations in CSD and non-CSD melanomas.
Among TERT-p mutants, the number of mutations correlated with the
risk of metastasis,8 and concurrent TERT-p and BRAF mutations
affected the risk of lymph node metastasis more than either mutation
alone.10 TERT-p mutant tumors were significantly associated with pri-
mary tumor location on the trunk with subsequent visceral metastasis
as the first site of progression in a study by Osella-Abate et al.18
TERT-p mutations have been significantly associated with
decreased disease-free and overall survival, although not as an inde-
pendently prognostic factor based on multivariate analysis.9 Addi-
tionally, two more recent series did not identify a significant
correlation between TERT-p mutational status and overall survival in
CSD and non-CSD melanomas.13,14 While the prognostic value of
TERT-p mutational status alone is equivocal in this context, the pres-
ence of concomitant TERT-p and BRAF11,13 or NRAS11 mutations was
significantly associated with decreased survival compared to WT
tumors. In a study by Nagore et al, tumors harboring both TERT-p
and BRAF or NRAS mutations were associated with fivefold
decreased melanoma-specific survival compared to tumors without
any of these mutations.11 ETS transcription factors are downstream
targets in the BRAF pathway, suggesting how coexistent mutations
in BRAF and TERT-p may confer poorer prognosis or more aggressive
behavior.10
In patients with CSD or non-CSD melanomas, the variant allele
rs2853669 polymorphism (−245 T > C) may modify the prognostic
impact of TERT-p mutations.11,12 The variant allele of this polymor-
phism disrupts the ETS2 site, inhibits binding of c-Myc to E-box, and
results in decreased promoter and telomerase activity.11 This is partic-
ularly significant given that this variant allele frequency may be as high
as 50%.19 TERT-p mutations, with or without concurrent BRAF/NRAS
mutations, did not reduce survival in patients who were carriers of the
variant allele rs2853669 polymorphism.11 Nagore et al separated a
series of predominantly nonacral melanomas were separated into two
groups: fast growing (≥0.5 mm/mo) vs slow growing (<0.05 mm/mo).
Growth rate was calculated by dividing Breslow depth by the time
elapsed between clinical suspicion and excision. TERT-p mutations,
with or without either concurrent BRAF or NRAS mutations, were
twice as common in fast growing compared to slow-growing melano-
mas. This effect on tumor growth was greater in patients who were
noncarriers for the variant allele rs2853669 polymorphism.12 Somatic
BRAF mutations are also less frequent in carriers of the variant allele
rs2853669 polymorphism and TERT-p WT or mutant melanomas.19
Less common TERT-p mutations may confer greater genomic
instability than hotspot mutations. Andrés-Lencina et al compared the
prognostic impact of the hotspot mutations and the −138/−139
CC > TT tandem mutation in a recent series. The tandem mutation
was significantly associated with all of the prognostic features corre-
lated with the −124:C > T hotspot mutation: Breslow depth >2 cm,
mitotic index, disease recurrence, tumor stage >IB, and disease-
specific death. Although the hotspot −124:C > T TERT-p mutation
results in higher promoter activity, the −138/−139 CC > TT tandem
mutation was associated with worse disease-free and melanoma-
specific survival separately or in combination with BRAF/NRAS
mutations.15
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3 | ACRAL MELANOMA
3.1 | Pathogenesis
In primary acral melanomas, TERT copy number gains (≥2) have been
detected in 24% to 44.9% of cases.20-22 Amplifications (defined by
gene copy number: chromosome control ratio ≥2) of TERT have been
identified by fluorescence in situ hybridization (FISH) in up to 21% of
acral melanomas. The majority of TERT amplifications are copy num-
ber transitions within 40 kb upstream of TERT.23,24 TERT-p hotspot
mutations are uncommon in primary cutaneous acral melanomas and
have only been detected in 4.2% to 19% of tumors
(Table 2).8,13,23,25,26,27
3.2 | Diagnosis
Diaz et al evaluated TERT copy number gains in acral melanomas and
nevi. While infrequent in the invasive component of acral melanomas,
copy number gains were identified within 100% of precursor MIS
evaluated. This discordance is most likely attributable to field cells:
clonally related melanocytes which arise in nonlesional epidermis
before the appearance of precursor lesions such as MIS. Thus, the
TERT copy numbers and amplifications observed in the invasive com-
ponent are more likely to be representative of tumorigenesis in acral
melanoma.22 In contrast, no copy number gains were identified in
24 acral nevi. IHC is less specific in this context; nuclear reactivity was
only detected up to 20% of cells in acral melanomas, failed to corre-
late with amplification, and was also detected in up to 10% of cells in
acral nevi.22
3.3 | Prognosis
TERT amplifications were significantly associated with decreased
overall survival in acral melanoma.24 Additionally, TERT copy number
gains in a series of 257 acral melanomas were associated with
increased relapse-free survival following adjuvant therapy with high-
dose interferon α-2b therapy; ulceration and tumor thickness >4 mm
were associated with >4 copy gains.21 In a large cohort of 1201 acral
melanomas with median follow-up of 29 months, Bai et al found that
TERT-p mutational status did not correlate with survival. Other series
confirmed the lack of prognostic value for TERT-p mutational status in
acral melanoma,13,14,26,27 although acral melanomas harboring TERT-p
TABLE 2 Acral melanoma8,13,14,20-27
Author
and year Number of cases Demographic Follow-up Major findings
Puig-Butille
et al20
17 Adults (age range 34-86 y) TERT copy number gains in 31%
Griewank
et al26
42 TERT-p mutations in 19% but not an
independent prognostic factor




TERT-p UV-signature mutations in 6% of primary
AMs but none of metastases
Heidenreich
et al8
24 TERT-p mutations in 4.2%
Diaz et al22 58:34 AMs; 24 AN AM: median 67 y (range
39-91)
AN: median 37 y (range
16-64)
TERT copy number gains in 24% of AMs and
100% of precursor MIS, but absent in AN;
Nuclear expression by IHC did not distinguish
AMs and AN
Diaz et al24 43 Adults, median age 71 y
(range 39-95)
TERT amplifications in 21% of AMs significantly





TERT-p hotspot mutations found in 7% of AMs
but did not correlate with survival
Bai et al14 1201 29 mo
(median)
TERT-p hotspot mutations in 11.4% of AMs but
did not correlate with survival
Roh et al13 46 TERT-p hotspot mutations found in 10.9% of
AMs and associated with increased Breslow
thickness but not an independent prognostic
factor
Yu et al21 573 TERT copy gains in 44.9% of tumors; associated
with ulceration, Breslow thickness >4 mm, and




197 TERT-p mutations in 5.3% and TERT
amplifications in 10.7% of tumors
Abbreviations: AM, acral melanoma; AN, acral nevi; IHC, immunohistochemistry; MIS, melanoma in situ; TERT-p, TERT promoter; UV, ultraviolet.
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hotspot mutations may have greater Breslow thickness compared to
WT tumors.13 Owing to the predominance of the acral melanoma sub-
type in Asian patients, TERT-p mutational status appears less
prognostically relevant in this population.14
4 | METASTATIC MELANOMA AND
MELANOMAS OF UNKNOWN PRIMARY
4.1 | Pathogenesis and diagnosis
TERT-p mutations have been identified in over half of primary and
metastatic melanomas, without significant difference in mutational
frequency between primary and metastatic tumors.28,29 TERT-p muta-
tions are not essential for tumor progression after locoregional
metastasis,29 and driver mutations in CDKN2A, PTEN, or TP53 are
more likely relevant than TERT-p at this stage.30 Within matched pri-
mary and metastatic tumors, discordant TERT-p mutational status has
been observed in 24% to 32% of cases.29,30 However, the discordance
rate decreases significantly after accounting for tumor heterogeneity
and subsequent metastasis. Among discordant pairs, mutational loss
(62%) is more frequent than acquisition (38%) in the metastatic
tumor.30 IHC does not appear valuable in this context: cytoplasmic
TERT expression did not correlate with TERT-p mutational status and
was discordant in 42% of matched pairs.29 In contrast to primary
mucosal melanomas, Egberts et al identified frequent TERT-p hotspot
mutations in melanomas of unknown primary, supporting a cutaneous
origin (Table 3).31
4.2 | Prognosis
Given the high prevalence of UV-signature mutations in metastatic mel-
anomas, TERT-p mutations may confer greater metastatic potential. In
203 nonacral cutaneous metastatic melanomas from 170 distinct
patients with a median follow-up time of 4 years, Ekedahl et al found
that 81% of patients had tumors with TERT-p mutations.32 In four
series, TERT-p mutations in metastatic tumors were not associated with
reduced survival.28,29,30,32 While adverse tumor characteristics—thicker
Breslow depth and higher mitotic rate by PHH3—were correlated with
TERT-p mutational status in one study, most series have not
reproduced this association.28,29,30,32 Thus, TERT-p WT metastases
may produce increased telomerase expression without TERT-p muta-
tions or depend on other driver mutations for progression.28,30,32 Simi-
larly, there was no association between TERT-p mutations and survival
in patients with melanoma of unknown primary.31
5 | MULTIPLE PRIMARY MELANOMAS
Pellegrini et al evaluated the mutational status of TERT-p in 97 mela-
nomas from 44 patients with multiple primary melanomas. Almost all
TABLE 3 Metastatic melanoma, MUP, and MPM28-33
Author and year Number of cases Demographic Follow-up Major findings
Egberts et al31 MUPs TERT-p hotspot mutations found in 67% of MUPs but did not
demonstrate prognostic value
Ekedahl et al32 203 nonacral cutaneous
metastatic melanomas
(170 distinct patients)
4 y (median) TERT-p UV-signature mutations in metastases from 81% of
patients but not a prognostic factor
Ofner et al28 115 primary and
metastatic melanomas
TERT-p mutations identified in 54.8%; no difference in
frequency between primary and metastatic tumors; no
prognostic value





TERT-p mutations identified in 68% of nodular melanomas and
64% of locoregional metastases; mutational status
associated with Breslow depth and mitotic index but not
survival; mutational status discordant in up to 24% of
matched cases; IHC (cytoplasmic expression) did not
correlate with mutational status but did correlate with
Breslow depth and reduced survival; IHC discordant in 42%
of matched cases
Yang et al30 43 pairs (matched
primary and metastatic
melanomas)
TERT-p mutations identified in 43% of primary melanomas and
29% of metastases but not a prognostic factor; discordant
mutational status in 32%, most often due to loss of
mutation
Pellegrini et al33 97 non-CSD melanomas
(44 patients with
MPM)
TERT-p mutations in 19.6% of tumors; intrapatient mutational
discordance was 45%
Abbreviations: IHC, immunohistochemistry; MPM, multiple primary melanomas; MUP, melanoma of unknown primary; non-CSD: non-chronic sun damage;
TERT-p: TERT promoter.
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the tumors assayed were non-CSD melanoma, and 75% were
metachronous. TERT-p hotspot mutations were found in 19.6% of
tumors, with a significant decrease in mutational frequency between
first and subsequent melanomas. The rate of intrapatient TERT-p
mutational discordance was 45%, highlighting the somatic heteroge-
neity of multiple primary melanomas (Table 3).33
6 | ATYPICAL SPITZOID NEOPLASMS
6.1 | Diagnosis and pathogenesis
TERT-p sequencing may aid in the distinction of atypical Spitz tumor
(AST) from spitzoid melanoma. In a series of three spitzoid melanomas
and six ASTs from pediatric and adult patients, Lee et al demonstrated
hotspot TERT-p mutations in all three spitzoid melanomas but in none
of the borderline spitzoid neoplasms. In a metastasis secondary to
spitzoid melanoma with fatal outcome, RT-PCR demonstrated signifi-
cantly elevated TERT mRNA expression, while TERT mRNA was
undetectable or expressed at low levels in nine ASTs.34 Epigenetic
upregulation by DNA methylation is unlikely to helpful in this context,
as none of these atypical spitzoid neoplasms demonstrated TERT-p
CpG methylation (Table 4).35
6.2 | Prognosis
TERT-p mutational status may also support risk stratification among
ASTs and spitzoid melanomas, given that the frequent presence of
lymph node metastasis in this context does not predict extranodal dis-
ease or death. In a study of 56 adult and pediatric patients with ASTs
or spitzoid melanomas by Lee et al, tumors harboring TERT-p hotspot
mutations were associated with distant metastasis and fatal outcome.
Ninety-three percent of patients had tumors with WT TERT-p and
were alive without distant metastasis at a follow-up period of
32.5 months.36 These findings were reproduced in two subsequent
smaller series of pediatric patients, in whom tumors with WT TERT-p
did not progress beyond lymph node metastasis.37,38 In atypical spit-
zoid neoplasms, the presence of a TERT-p hotspot mutation has also
been associated with age ≥10, mitotic rate > 5 mm2, and ulceration.36
7 | CONVENTIONAL AND NEVOID
MELANOMAS IN PEDIATRIC PATIENTS
7.1 | Pathogenesis
Similar UV-signature TERT-p mutations drive tumorigenesis in pediat-
ric and adult conventional melanoma. In a series of 15 conventional
melanomas from pediatric patients, Lu et al identified TERT-p muta-
tions in 92% of sequenced tumors, and 80% of these mutations were
UV signature. The single conventional melanoma with wild-type
TERT-p was an AM. Additionally, 87% of tumors contained an activat-
ing BRAF V600 mutation.37 TERT-p mutant status in pediatric conven-
tional melanoma correlates with—but is not required for—telomerase
expression: TERT-p hypermethylation may also increase TERT mRNA
expression.34,35 In a series of 19 conventional melanomas in pediatric
patients, TERT-p hotspot mutations and hypermethylated CpG sites
were identified in 53% and 42% of tumors, respectively.
Rearrangements involving the TERT locus were also demonstrated by
FISH in two of eight conventional melanomas. In contrast, none of
these aberrations that increase telomerase expression were present in
two nevoid melanomas (Table 5).39
7.2 | Prognosis
TERT-p methylation—alone or with concomitant TERT-p hotspot
mutation—is associated with reduced recurrence-free survival, but not
overall survival. Of note, TERT-p mutations alone did not predict
adverse outcomes in pediatric conventional melanoma in the largest
series to date by Seynnaeve et al.39




cases Demographic Follow-up Major findings




TERT-p hotspot mutations in 7% associated with
distant metastasis and fatal outcome
Lu et al37 5 Pediatric Mean
32 mo
Single SM with TERT-p hotspot mutation associated
with distant metastasis and fatal outcome
Wu et al38 7 Pediatric; age range 2-14 y Median
20 mo
Two tumors with TERT-p hotspot mutations
associated with distant metastasis and fatal
outcome
Lee et al34 9 Pediatric and adult TERT-p hotspot mutations and increased TERT
mRNA expression associated with SM
Fan et al35 9 Pediatric and adult TERT-p CpG methylation did not distinguish SM and
AST
Abbreviations: AST, atypical spitz tumor; SM, spitzoid melanoma; TERT-p, TERT promoter.
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8 | MELANOMA ARISING IN
CONGENITAL NEVI
Methylation-dependent epigenetic upregulation of TERT may play a
role in the pathogenesis of melanoma arising in giant congenital nevi
(GCN) and allow differentiation from proliferative nodules in GCN. In
three melanomas with WT TERT-p arising in congenital nevi, next-
generation sequencing of TERT-p demonstrated that almost all CpG
sites sequenced were highly methylated. In contrast, the same region
of TERT-p was predominantly unmethylated in three GCN with prolif-
erative nodules. TERT-p methylation also correlated strongly with tel-
omerase expression assayed by TERT mRNA in situ hybridization
(ISH).35 In a follow-up study, real-time (RT) quantitative PCR of metas-
tases secondary to two of these melanomas arising in GCN demon-
strated a 20- to 27-fold increase in TERT mRNA expression
(Table 6).34
9 | DESMOPLASTIC MELANOMA
In a series of 76 desmoplastic melanomas, Yang et al identified TERT-p
mutations in 34% of tumors. Desmoplastic melanomas characterized
by at least 90% paucicellular spindle cells and stromal fibrosis were
classified as pure, while those with greater than 10% cellular foci or
epithelioid cytomorphology and without stromal fibrosis were classi-
fied as mixed.40,41,42 Mixed desmoplastic melanoma was three times
more likely than pure desmoplastic melanoma to harbor TERT-p
hotspot mutations as well as other mutations upstream of the ATG
start site. Thus, loss of telomere integrity may be more relevant to the
pathogenesis of mixed desmoplastic melanoma than of pure
desmoplastic melanoma. TERT-p mutational status is not significantly
associated with ulceration, the presence of mitotic figures, perineural
invasion, BRAF mutations, or Breslow depth in mixed or pure
desmoplastic melanoma.43
10 | DIFFERENTIATION OF RECURRENT
MELANOMA FROM RECURRENT NEVI
In a study by Walton et al, TERT-p hotspot mutations were identified
in four of six recurrent melanomas and none of 17 recurrent nevi,
suggesting the diagnostic specificity of TERT-p sequencing in challeng-
ing cases with overlapping histopathological features such as
dyscohesion of the dermoepidermal junction, epidermal effacement,
and nuclear atypia.7
11 | CONCLUSION
The exact role of molecular analysis of TERT and TERT-p analysis in
routine practice still needs to be refined. There is data demonstrating
that TERT-p mutations are relatively sensitive and specific in differen-
tiating some subsets of melanoma from nevi. However, the greatest
utility for TERT-p mutational analysis is for borderline lesions that are
not obviously benign or malignant by histopathological examination
alone. In this area, there is still a lack of robust studies that correlate
TABLE 5 Conventional and nevoid melanomas in pediatric patients34,35,37,39
Author
and year Number of cases Demographic
Follow-
up Major findings
Lu et al37 15 Median age 16 y (range
11-20)
Twelve of thirteen tumors with TERT-p mutations,
predominantly UV-signature
Lee et al34 TERT-p mutations or TERT-p hypermethylation can
increase TERT mRNA expression in pediatric CM
Fan et al35 TERT-p mutations or TERT-p hypermethylation can
increase TERT mRNA expression in pediatric CM
Seynnaeve
et al39
21 (19 CM, 2 nevoid
melanoma)
Median age 21 y (range
13-25)
TERT-p mutations, hypermethylation, and increased
TERT mRNA expression in CMs; hypermethylation
associated with reduced recurrence-free survival
Abbreviations: CM, conventional melanoma; TERT-p, TERT promoter; UV, ultraviolet.
TABLE 6 Melanoma arising in GCN34,35
Author
and year Number of cases Demographic
Follow-
up Major findings
Fan et al35 Six: (three melanomas; three proliferative
nodules)
Hypermethylation of WT TERT-p and increased TERT
mRNA expression observed in melanoma but absent
in proliferative nodules
Lee et al34 Two metastatic melanomas Metastases from melanoma arising in GCN also
demonstrate increased TERT mRNA expression
Abbreviations: GCN, giant congenital nevi; TERT-p, TERT promoter; WT, wild type.
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TERT-p mutational status with outcome data in histopathologically
ambiguous melanocytic lesions for which this molecular study may be
helpful.
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